Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia

Infection

Volumn 42, Issue 1, 2014, Pages 207-210

  Pea, F ^a,b   Crapis, M ^a   Cojutti, P ^a,b   Bassetti, M ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Augmented clearance; Clinical pharmacology; Daptomycin; Intravenous drug use; Therapeutic drug monitoring

Indexed keywords

BENZODIAZEPINE DERIVATIVE; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; DAPTOMYCIN; DELORAZEPAM; GLUCOSE; HEMOGLOBIN; LEVOFLOXACIN; METHADONE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SODIUM;

ABDOMINAL MASS; ADULT; ANTIMICROBIAL THERAPY; ARTERY LESION; ARTICLE; BACTEREMIA; BLOOD CULTURE; CASE REPORT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; ENDOVASCULAR SURGERY; FALSE ANEURYSM; FEMORAL ARTERY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPOALBUMINEMIA; INGUINAL REGION; INTRAVENOUS DRUG ABUSE; LABORATORY TEST; LEUKOCYTE; LOADING DRUG DOSE; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL HISTORY; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NECROTIZING FASCIITIS; OPIATE ADDICTION; SIDE EFFECT; SKIN ALLERGY; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SUBCUTANEOUS TISSUE; SUBSTITUTION THERAPY; WOUND; YOUNG ADULT;

ANALGESICS, OPIOID; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG INTERACTIONS; DRUG USERS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; PLASMA; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84898546619     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0511-2     Document Type: Article

References (17)

1. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother. 2008;62:iii15-23.
2. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52:1-8.
3. Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8:5-12.
4. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care. 2009;13:214.
5. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32:1535-41. (Pubitemid 38925182)
6. Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011;45:e37.
7. Coughlin PA, Mavor AI. Arterial consequences of recreational drug use. Eur J Vasc Endovasc Surg. 2006;32:389-96. (Pubitemid 44341106)
8. Keeling AN, McGrath FP, Lee MJ. Interventional radiology in the diagnosis, management, and follow-up of pseudoaneurysms. Cardiovasc Intervent Radiol. 2009;32:2-18.
9. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillinresistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother. 2007;51:1787-94. (Pubitemid 46744159)
10. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-8. (Pubitemid 38040177)
11. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-23. (Pubitemid 36368592)
12. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother. 1992;36:1109-14.
13. King CH, Creger RJ, Ellner JJ. Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Antimicrob Agents Chemother. 1985;27:285-90. (Pubitemid 15144685)
14. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, Thompson GA, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother. 1991;35:696-700.
15. Gutkowska J, Schiller PW. Renal effects of TAPP, a highly selective mu-opioid agonist. Br J Pharmacol. 1996;119:239-44. (Pubitemid 26326454)
16. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob Agents Chemother. 2007;51:2748-57. (Pubitemid 47206209)
17. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50:1568-74.